

Award Number:
W81XWH-10-1-0645

TITLE:
Convection-Enhanced Delivery (CED) in an Animal Model of Malignant
Peripheral Nerve Sheath (MPNST) Tumors and Plexiform Neurofibromas (PN)

PRINCIPAL INVESTIGATOR:
Kaleb Yohay, M.D.

CONTRACTING ORGANIZATION:
Weill Medical College of Cornell University
1300 York Avenue
New York, NY 10065-4805

REPORT DATE:
September 2012

TYPE OF REPORT:
Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

- ☒ Approved for public release; distribution unlimited
- ☐ Distribution limited to U.S. Government agencies only;
report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE September 2012		2. REPORT TYPE Annual		3. DATES COVERED 15 August 2011 - 14 August 2012	
4. TITLE AND SUBTITLE Convection enhanced delivery (CED) in an animal model of malignant peripheral nerve sheath tumors and plexiform neurofibromas				5a. CONTRACT NUMBER W81XWH-10-1-0645	
				5b. GRANT NUMBER W81XWH-10-1-0645	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Kaleb Yohay E-Mail: kay2003@med.cornell.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Weill Medical College of Cornell University 1300 York Avenue New York, NY 10065-4805				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Our experiments for the current study are ongoing. We have encountered several challenges in completing this. Work on this project was initially delayed by several months secondary to difficulty in obtaining regulatory approval from both our own IACUC and the DOD. Additionally, though we were able to establish and maintain an MPNST cell line suitable for our needs, we have been unable to maintain a cell line for benign plexiform neurofibroma. We have not been able to successfully establish the xenograft within the sciatic nerve. Using the MPNST cell line we were able to perform in vitro studies, comparing efficacy of erlotinib, rapamycin and imatinib in inhibition of cell proliferation and established that erlotinib is the most potent inhibitor for this particular cell line. The cell line we are using is aggressive and grows rapidly as a flank xenograft though we have not been able to successfully establish the xenograft within the sciatic nerve.					
15. SUBJECT TERMS Convection-Enhanced Delivery (CED), Malignant Peripheral Nerve Sheath (MPNST), Plexiform Neurofibromas (PN), Neurofibromatosis Type 1 (NF1)					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	2
Key Research Accomplishments.....	2
Reportable Outcomes.....	2
Conclusion.....	3
References.....	3
Appendices.....	3
Supporting Data.....	4

Convection enhanced delivery (CED) in an animal model of malignant peripheral nerve sheath tumors and plexiform neurofibromas.

PI: Kaleb Yohay

Introduction

Neurofibromatosis Type 1 (NF1) is a common autosomal dominant neurocutaneous disorder that results in a predisposition to the development of benign and malignant tumors. Plexiform neurofibromas (PN) are complex, often large tumors that usually involve multiple nerves and may cause significant morbidity. Complete surgical resection is rarely feasible. PNs may undergo malignant transformation to become Malignant Peripheral Nerve Sheath Tumors (MPNST). MPNSTs are aggressive, often fatal sarcomas and are the leading cause of death in adults with NF. Currently there are no available effective medical therapies for PNs or MPNST. EGFR is not normally expressed by Schwann cells, however, EGFR expression has been demonstrated in association with the development of benign and malignant peripheral nerve sheath tumors, making this receptor a potential therapeutic target. Effective in vivo delivery of traditional chemotherapy and newer molecularly targeted therapeutics to tumors of the nervous system remains a significant obstacle. Systemic delivery is restricted by systemic toxicity, non-targeted distribution and subtherapeutic tumor levels of potentially curative agents. Interstitial infusion, also referred to as convection-enhanced delivery (CED), is a mode of local drug delivery which relies on a pressure-dependent gradient to accomplish uniform infusate dispersion and high drug concentrations directly in tumor or tissue while avoiding systemic exposure and hence dose-limiting toxicity.

In this study we had proposed that CED may be used as a safe, reliable and effective means of delivery of therapeutic agents in animal models of plexiform neurofibromas and malignant peripheral nerve sheath tumors.

Specific Aim 1: To use an animal model to determine the distribution of macromolecules delivered to intraneural PNs and MPNST via CED.

Design: Orthotopic xenograft models of sciatic intraneural NF1 MPNST and PNs in scid mice as described by Perrin et al. (2007a, 2007b) were to be used. Six to eight weeks after implantation, the location and extent of tumor development within the sciatic nerve will be assessed by MRI. The sciatic nerve tumor will be surgically exposed and a silica infusion catheter will be placed within the tumor. HRP-labeled albumin or gadolinium-albumin will be infused. Several infusion rates and volumes will be assessed. Volume of distribution within the tumor and sciatic nerve will be assessed with immunohistochemistry and in vivo MRI.

Specific Aim 2: To determine the efficacy CED of the epidermal growth factor receptor (EGFR) inhibitor erlotinib in animal models of intraneural PNs and MPNST.

Design: Orthotopic xenograft models of sciatic intraneural NF1 MPNST and PNs in scid mice were to be used. EGFR positive cell lines were to be used for implantation. Six to eight weeks after implantation, the location and extent of tumor development within the sciatic nerve will be assessed by MRI. Erlotinib or vehicle will be infused into the tumor via CED using the infusion parameters optimized from the results of Specific Aim 1. Tumor growth and angiogenesis will be monitored by in vivo contrast enhanced MRI at several time points after infusion and tumor growth will be compared in erlotinib versus vehicle treated animals. Phosphorylated Akt and EGFR will be measured in tumor samples to assess for biologic activity of the erlotinib.

Body

We have encountered several challenges in completing this study as proposed. Several factors have contributed to our inability complete the work as planned. Work on this project was initially delayed by several months secondary to difficulty in obtaining regulatory approval from both our own IACUC and the DOD. Additionally, though we have been able to establish and maintain an MPNST cell line suitable for our needs, we have been unable to maintain a cell line for benign plexiform neurofibroma. As such, we have modified our proposal to utilize only an MPNST xenograft model and not a PN xenograft model. Additionally, in order to maximize our chance of success in the treatment efficacy experiments, we spent additional time testing agents to compare efficacy to erlotinib in vitro, including rapamycin and imatinib (See Supporting Data Fig. 1).

In order to refine our methods and ensure our ability to complete the study, we have partnered with Dr. Gary Schwartz at Memorial Sloan Kettering Cancer Center whose lab works extensively with MPNST cell lines and xenograft models. Additionally, we are partnering with members of the Robert Martuza Lab at the Massachusetts General Hospital to refine our techniques for sciatic nerve xenografting of MPNST cells.

At this point we have characterized our MPNST cell line, established that erlotinib is the most promising of the three agents tested for this particular cell line, and we have established the surgical procedures necessary for the sciatic xenograft model. The cell line we are using is aggressive and grows rapidly as a xenograft (see Supporting Data Fig 2) which should allow for a shorter time between tumor implantation and treatment. With an accelerated schedule, with a reduction in the number of animals to be implanted by $\frac{1}{2}$ (since we will not be proceeding with the plexiform neurofibroma xenografts), and with the additional support and expertise from our new collaborators, we are confident that we will be able to produce valuable and accurate data within the time frame of the grant.

Key Research Accomplishments

Characterization of the status of signaling molecules of MPNST cells: Phosphorylated EGFR positive status was confirmed for our cell line.

Determination of the surgical procedures: Utilizing mouse cadavers, we have refined our techniques for tumor cell implantation and drug delivery using convection-enhanced delivery (CED).

Relative Growth of MPNST cells in vivo treated with rapamycin, imatinib or erlotinib: Erlotinib demonstrated the most potent growth inhibition in vitro of the agents tested (See Supporting Data Fig 1).

Establishment of a MPNST flank xenograft tumor model: Utilizing our MPNST cell line we were unable to establish a sciatic xenograft model but were able to establish a successful flank xenograft model (see Supporting Data Fig 2).

Reportable Outcomes

None

Conclusions

We have characterized our MPNST cell line, established that erlotinib is the most promising of the three agents tested for this particular cell line, and we have established the surgical procedures necessary for the sciatic xenograft model. The cell line we are using is aggressive and grows rapidly as a xenograft which should allow for a shorter time between tumor implantation and treatment. We cannot make any conclusions about the relative feasibility or efficacy of convection enhanced delivery in malignant peripheral nerve sheath tumors or plexiform neurofibromas at this time.

References

Perrin GQ, Fishbein L, Thomson SA, et al., Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. J Neurosci Res, 2007. 85(6): p. 1347-1357.

Perrin GQ, Li H, Fishbein L, et al., An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Lab Invest, 2007. 87(11): p. 1092-1102.


Appendices

None.


Supporting Data

Figure 1:


Relative Growth of MPNST cells in vivo treated with rapamycin, imatinib or erlotinib.



Rapamycin



Imatinib



Erlotinib (least soluble; max = 50um)

Figure 2:
MPNST flank xenograft tumor volume.

